Related Experiment Video

Updated: Mar 8, 2026

Induced Differentiation of M Cell-like Cells in Human Stem Cell-derived Ileal Enteroid Monolayers
11:34

Induced Differentiation of M Cell-like Cells in Human Stem Cell-derived Ileal Enteroid Monolayers

Published on: July 26, 2019

9.2K

The effect of polymeric formula on enterocyte differentiation

Gabrielle R Budd1, Alan Aitchison1, Andrew S Day2

  • 11 Department of Surgery, University of Otago Christchurch, Christchurch, New Zealand.

Innate Immunity
|January 21, 2017
PubMed

Insights

Exclusive enteral nutrition, a therapy for Crohn's disease (CD), may work by increasing intestinal alkaline phosphatase (IAP). This enzyme strengthens the gut's innate immune response to bacteria, potentially aiding CD remission.

Area of Science:

  • Gastroenterology
  • Immunology
  • Cell Biology

Background:

  • Exclusive enteral nutrition (EEN) is a primary treatment for active Crohn's disease (CD), particularly in pediatric patients.
  • The precise mechanisms underlying EEN's therapeutic effects in CD remain incompletely understood.
  • Intestinal alkaline phosphatase (IAP) is a known marker of enterocyte differentiation and plays a role in the gut's innate immunity.

Purpose of the Study:

  • To investigate the effect of polymeric formula (PF) on intestinal alkaline phosphatase (IAP) expression in intestinal cells.
  • To explore potential mechanisms by which EEN might modulate the gut's immune response in the context of Crohn's disease.

Main Methods:

  • Utilized the Caco-2 human adenocarcinoma cell line.
  • Incubated Caco-2 cells with a polymeric formula (PF).
  • Quantified the expression of cell surface-associated intestinal alkaline phosphatase (IAP).

Main Results:

  • Incubation with polymeric formula (PF) led to a dose-dependent increase in cell surface IAP expression.
  • This suggests PF influences IAP levels in intestinal cells.
  • The findings indicate a potential role for IAP modulation in EEN's efficacy.

Conclusions:

  • Cell surface-associated IAP expression is enhanced by polymeric formula (PF) in vitro.
  • This enhancement may represent a mechanism by which EEN strengthens the gut's innate immune response.
  • Further research is needed to elucidate the specific pathways involved and confirm these findings in vivo for Crohn's disease patients.

Keywords:
Crohn’s diseasecellular differentiationenteral nutritionintestinal alkaline phosphatasevitamin D receptor

More Related Videos

Alginate Microcapsule as a 3D Platform for Propagation and Differentiation of Human Embryonic Stem Cells hESC to Different Lineages10:01

Alginate Microcapsule as a 3D Platform for Propagation and Differentiation of Human Embryonic Stem Cells hESC to Different Lineages

Published on: March 9, 2012

16.8K
Establishment of Human Epithelial Enteroids and Colonoids from Whole Tissue and Biopsy06:33

Establishment of Human Epithelial Enteroids and Colonoids from Whole Tissue and Biopsy

Published on: March 6, 2015

36.1K

Related Concept Videos

Factors Affecting Dissolution: Polymorphism, Amorphism and Pseudopolymorphism01:21

Factors Affecting Dissolution: Polymorphism, Amorphism and Pseudopolymorphism

Polymorphism refers to the existence of a drug substance in multiple crystalline forms, known as polymorphs. Recently, this term has been expanded to include solvates (forms containing a solvent), amorphous forms (non-crystalline forms), and desolvated solvates (forms from which the solvent has been removed).
Some polymorphic crystals possess lower aqueous solubility than their amorphous counterparts, leading to incomplete absorption. For instance, the oral suspension of Chloramphenicol, which...
805
Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence01:27

Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence

Changes in polymorphic forms can significantly influence the bioavailability of poorly soluble drugs. Although the FDA defines pharmaceutical equivalence based on having the same active ingredient, dosage form, and route of administration, it does not automatically disqualify products with different polymorphic forms. This means two products with different polymorphs can still be deemed pharmaceutically equivalent. However, polymorphic differences can affect properties like wettability,...
209
Site-Targeted Drug Delivery Systems: Polymeric Carriers01:24

Site-Targeted Drug Delivery Systems: Polymeric Carriers

Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...
68
iPS Cell Differentiation01:22

iPS Cell Differentiation

The ability of induced pluripotent stem cells or iPSCs to differentiate into most body cell types has stimulated repair and regenerative medicine research over the past few decades. iPSC-derived blood cells, hepatocytes, beta islet cells, cardiomyocytes, neurons, and other cell types can repair injuries or regenerate damaged tissue in diseases such as diabetes and neurodegenerative disorders.
3.2K